Introduction {#S1}
============

Rasmussen encephalitis (RE) is a very rare neurological disorder of unknown etiology for which there is no known cure. The disease primarily affects young children starting around 6 years of age (range 1--14 years), and if untreated results in permanent deficits affecting motor and sensory systems ([@B1]--[@B3]). In general patients first present with partial (focal) seizures that are refractory to antiepileptic drug therapy; seizures may spread to ipsilateral brain seriously impacting intellectual development. Magnetic resonance images show areas of inflammation and atrophy usually in one cerebral hemisphere ([@B1]). Immunosuppressive therapies have been partially effective ([@B4]--[@B8]), although surgery may ultimately be the only treatment option that can control the intractable seizures.

Examination of resected brain tissue indicates that the inflammatory reaction in RE involves activated brain resident macrophages (microglia) and both αβ and γδ T cells ([@B9]--[@B13]). CD8^+^ T cells with polarized granzyme B-containing granules have been observed in sections of resected brain tissue in close apposition to both neurons and astrocytes ([@B9], [@B14]), suggesting that they may have formed immunological synapses and may be engaged in MHC class I-restricted cell killing. By contrast, cytotoxic γδ T cells do not depend on antigen presentation by classical MHC molecules ([@B15]--[@B17]). Clonal expansion of αβ T cells in RE brain tissue and in blood has been documented providing evidence for an antigen-driven immune response in RE ([@B18], [@B19]). More recently, deep sequencing the third complementarity regions (CDR3s) of the T cell receptor (TCR) β locus from cDNA prepared from CD8^+^ peripheral blood mononuclear cells (PBMCs) from 23 RE cases and from five RE brain tissue specimens has confirmed this observation and has identified potentially RE-specific T cell clones ([@B20]). Similarly, we have shown that Vδ1^+^ γδ T cells in RE brain tissue are clonally restricted ([@B13]).

To gain further insight into the involvement of αβ T cells in RE, we carried out deep sequencing of rearranged TCR β CDR3s from genomic DNA isolated from matched blood and brain tissue from 14 RE surgery cases. By comparing these sequences to blood from 14 other pediatric epilepsy surgery cases and a cohort of 100 normal individuals, we identified clonally expanded private (patient-specific) and public T cells in RE brain tissue.

Several alleles of classical human leukocyte antigen (HLA) genes in the MHC locus have been linked to autoimmune diseases. We sequenced the major HLA I and II genes in 24 RE cases and found that 16 of these RE cases carried HLA I and/or II alleles that have been linked to the risk of contracting an autoimmune disease.

Materials and Methods {#S2}
=====================

All of the surgical specimens used in this study were obtained under IRB approval (UCLA IRB nos. 11-00030 and 13-001213) with informed consent and in compliance with HIPAA requirements, as part of a multi-institutional RE tissue transfer program ([@B21]). All of the RE patients in the study cohort were Caucasian with a median age of 8.5 years (range 3--14.4 years) at the time of surgery. All specimens and patient data were de-identified, and there were no exclusion criteria. Treatment histories prior to surgery were not available for all of the RE cases. Genomic DNA was prepared from flash-frozen blocks of involved tissue and from whole blood, collected at the time of surgery, using a DNAeasy blood and tissue kit (Qiagen, Valencia, CA, USA). Access to a database of TCR β CDR3 sequences from anonymized healthy control blood samples was provided by Adaptive Biotechnologies (Seattle, WA, USA).

HLA Sequencing {#S2-1}
--------------

A TrueSight^®^ HLA sequencing panel (Illumina, San Diego, CA, USA) was used to obtain in-depth sequence information about the eight major HLA genes (HLA-A, B, C, DRPA1, DRPB1, DRQA1, DRQB1, DRB1/3/4/5) in 24 RE genomic DNA samples. Barcoded libraries were sequenced on a MiSeq platform (Illumina), and FASTQ files were uploaded to BaseSpace (Illumina). Assignments of HLA alleles were made using ConnexioAssign™ v1.0 TrueSight^®^ HLA analysis software (Illumina).

TCR Vβ Sequencing {#S2-2}
-----------------

An ImmunoSEQ kit (Adaptive Biotechnologies) was used to generate libraries of Vβ CDR3 sequences from 42 genomic DNA samples. The kit incorporates a two-step amplification bias-controlled PCR approach and barcoded spiked-in synthetic templates in order to measure the degree of sequencing coverage and residual PCR bias ([@B22], [@B23]). The CDR3 libraries were sequenced on a MiSeq platform (Illumina), and FASTQ files were uploaded to BaseSpace (Illumina) and curated at Adaptive Biotechnologies. To merge closely related sequences, the data were filtered and clustered using both the relative frequency ratio between similar clones and a modified nearest-neighbor algorithm. The resulting sequences were annotated according to the IMGT database[^1^](#fn1){ref-type="fn"} ([@B24]). The TCR sequences were normalized to correct for residual multiplex PCR amplification bias and quantified against a set of synthetic TCR β CDR3 sequences. The data were further curated *via* the IMGT HighV-QUEST web portal to remove all non-productive rearrangements ([@B25]). Clonality was calculated as described by Harden et al. ([@B26]). Graphs and statistical analysis utilized Microsoft Excel^®^ (Microsoft Corporation, Redmond, WA, USA) and R-project programs.[^2^](#fn2){ref-type="fn"} Curve fitting utilized EasyFit5.6 Professional,[^3^](#fn3){ref-type="fn"} relative risks were determined using an online calculator,[^4^](#fn4){ref-type="fn"} Venn diagrams were constructed using online software,[^5^](#fn5){ref-type="fn"} and the heat map was generated with GENE-E bioinformatics software tools.[^6^](#fn6){ref-type="fn"} Plots were exported to CorelDRAW X6 (Corel Corporation, Ottawa, ON, Canada).

Results {#S3}
=======

RE Patients Carry Autoimmune Disease-Associated HLA Alleles {#S3-1}
-----------------------------------------------------------

We obtained sequence information for the major HLA genes from 24 RE cases (Table S1 in Supplementary Material). Strikingly, two unrelated patients, RECP43 and RECP48, had the identical HLA haplotype (Table S1 in Supplementary Material). Table [1](#T1){ref-type="table"} lists the alleles that were shared by four or more cases; DPA1\*01:03:01:01 was the most frequent allele, but this may be expected from the demographics of our patient cohort; in a study of 5,944 stem cell donors self-identified as European Caucasian, the allelic frequency of DPA1\*01:03 was 0.8186 ([@B27]). The allelic frequencies for all but three of the overlapping HLA alleles have been reported for a population of 220 Caucasians from the San Francisco Bay Area[^7^](#fn7){ref-type="fn"} ([@B28], [@B29]), which allowed us to calculate provisional relative risks. Compared with this reference population, three alleles were associated with a statistically significant (*P* \< 0.05) increased relative risk of RE, C\*07:02:01:01, DQA1\*04:01:01, and DQB1\*04:02:01 (Table [1](#T1){ref-type="table"}). Six patients carried both DQA1\*04:01:01, and DQB1\*04:02:01 suggesting that these gene products form a heterodimer. It will be necessary to screen a larger cohort of RE patients to substantiate the risk alleles that we have identified.

###### 

**Frequency of human leukocyte antigen alleles in a cohort of Rasmussen encephalitis patients**.

  Allele              Allele frequency   Allele frequency (USA, a Caucasian population)   Relative risk   95% CI            *P*-value[\*](#tfn1){ref-type="table-fn"}
  ------------------- ------------------ ------------------------------------------------ --------------- ----------------- -------------------------------------------
  A\*02:01:01:01      0.229              0.242                                            0.9424          0.5468--1.6242    0.84186
  A\*03:01:01:01      0.167              0.148                                            1.1282          0.5766--2.2075    0.73775
  A\*24:02:01:01      0.104              0.75                                             1.3889          0.5691--3.3895    0.47993
  A\*29:02:01:01      0.104              0.48[^a^](#tfn2){ref-type="table-fn"}            2.1825          0.8622--5.5245    0.09930
  B\*07:02:01         20.8               0.124                                            1.6667          0.9107--3.0501    0.09733
  B\*44:03:01:01      0.104              0.053[^b^](#tfn3){ref-type="table-fn"}           1.9928          0.7941--5.0009    0.14216
  C\*04:01:01:01      0.083              0.102                                            0.8148          0.3063--2.1673    0.69472
  C\*05:01:01:01      0.083              0.076                                            1.1111          0.4112--3.0023    0.84629
  C\*07:02:01:01      0.25               0.141                                            1.7742          1.0323--3.0494    0.03767
  DPA1\*01:03:01:01   0.75               Not reported                                                                       
  DPA1\*02:02:02      0.083              Not reported                                                                       
  DPB1\*01:01:01      0.125              0.057[^c^](#tfn4){ref-type="table-fn"}           2.2             0.95--5.0947      0.06533
  DPB1\*04:01:01:01   0.375              0.407[^d^](#tfn5){ref-type="table-fn"}           1.257           0.8551--1.8478    0.24719
  DPB1\*04:02:01:01   0.125              0.105[^e^](#tfn6){ref-type="table-fn"}           1.1957          0.5389--2.6527    0.67329
  DQA1\*02:01         0.146              0.118[^f^](#tfn7){ref-type="table-fn"}           1.234           0.5943--2.5624    0.58465
  DQA1\*01:02:01:01   0.167              0.225                                            0.7407          0.3844--1.4274    0.37619
  DQA1\*03:01:01      0.125              0.159                                            0.7857          0.3606--1.7118    0.55516
  DQA1\*04:01:01      0.146              0.034                                            4.5833          1.9453--10.786    0.00053
  DQA1\*05:01:01:01   0.083              0.261[^g^](#tfn8){ref-type="table-fn"}           0.3188          0.1231--0.8255    0.01840
  DQA1\*05:05:01:01   0.125              Not reported                                                                       
  DQB1\*02:01:01      0.083              0.153                                            0.5473          0.2087--1.4348    0.22232
  DQB1\*02:02:01      0.083              0.089[^h^](#tfn9){ref-type="table-fn"}           0.9402          0.3511--2.5175    0.91006
  DQB1\*03:01:01:01   0.146              0.158[^i^](#tfn10){ref-type="table-fn"}          0.93            0.4535--1.9070    0.85357
  DQB1\*04:02:01      0.167              0.027[^j^](#tfn11){ref-type="table-fn"}          6.1111          2.6289--14.2059   \<0.0001
  DQB1\*06:02:01      0.104              0.155                                            0.674           0.2858--1.5895    0.37375
  DRB1\*03:01:01:01   0.083              0.145                                            0.5729          0.2182--1.5041    0.26101
  DRB1\*07:01:01:01   0.146              0.12                                             1.2107          0.5836--2.5116    0.62007
  DRB1\*15:01:01:01   0.146              0.159                                            0.9167          0.4473--1.8787    0.82381

*\**P* values are calculated from 95% confidence intervals according to Altman and Bland ([@B30])*.

*^a^A\*29:02:01*.

*^b^B\*44:03:01*.

*^c^DPB1\*01:01*.

*^d^DPB1\*04:01:01*.

*^e^DPB1\*04:02*.

*^f^DQA1\*01:02:01*.

*^g^DQA1\*05:01:01*.

*^h^DQB1\*02:02*.

*^i^DQB1\*03:01:01*.

*^j^DQB1\*04:02:01*.

It is interesting to note that HLA-C\*07 has been reported to be a risk factor for Graves disease, an autoimmune disease that affects the thyroid gland ([@B31]). Of the 10 RE cases that carried HLA-C\*07:02:01:01, six of them were also positive for HLA-A\*03:01:01:01, which has been linked to MS ([@B32]) (Table [2](#T2){ref-type="table"}). HLA class II alleles found in our patient cohort have also been associated with autoimmunity. As shown in Table [3](#T3){ref-type="table"}, four RE patients were positive for the DRB1\*03:01-DQA1\*05:01-DQB1\*02:01 haplotype (DR3 serotype) that confers susceptibility to type 1 diabetes ([@B33]), likewise the haplotype DRB1\*15:01-DQA1\*01:02-DQB1\*0602 increases the risk of contracting MS ([@B32]), and five different RE patients carried all three alleles (Table [3](#T3){ref-type="table"}). These data suggest that some RE cases might be associated with an autoimmune response.

###### 

**Rasmussen encephalitis cases in the study cohort carrying human leukocyte antigen (HLA) class I alleles that have been linked to an autoimmune disease**.

           HLA A            HLA B            HLA C                                              
  -------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  RECP03   A\*03:01:01:01   A\*32:01:01      B\*44:02:01:01   B\*40:02:01      C\*03:04:01:01   C\*05:01:01:01
  RECP12   A\*03:01:01:01   A\*33:01:01      B\*07:02:01      B\*27:03         C\*07:02:01:01   C\*02:02:02:01
  RECP16   A\*03:01:01:01   A\*24:02:01:01   B\*14:02:01:01   B\*39:06:02      C\*07:02:01:01   C\*08:02:01:01
  RECP26   A\*03:01:01:01   A\*24:02:01:01   B\*07:02:01      B\*27:05:02      C\*07:02:01:01   C\*01:02:01
  RECP27   A\*03:01:01:01   A\*02:01:01:01   B\*07:02:01      B\*39:06:02      C\*07:02:01:01   C\*07:02:01:01
  RECP34   A\*03:01:01:01   A\*24:02:01:01   B\*07:02:01      B\*13:02:01      C\*07:02:01:01   C\*06:02:01:01
  RECP39   A\*03:01:01:01   A\*02:01:01:01   B\*07:02:01      B\*07:02:01      C\*07:02:01:01   C\*07:02:01:01
  RECP40   A\*68:01:02:01   A\*68:01:02:01   B\*07:02:01      B\*40:01:02      C\*07:02:01:01   C\*03:04:01:01
  RECP42   A\*11:01:01:01   A\*23:01:01      B\*07:02:01      B\*07:05:01      C\*07:02:01:01   C\*15:05:02
  RECP45   A\*24:02:01:01   A\*02:01:01:01   B\*15:01:01:01   B\*39:06:02      C\*07:02:01:01   C\*03:03:01
  RECP49   A\*03:01:01:01   A\*29:02:01:01   B\*07:02:01      B\*14:02:01:01   C\*07:02:01:01   C\*08:02:01:01

*RECP, Rasmussen Encephalitis Children's Project*.

###### 

**Rasmussen encephalitis cases in the study cohort carrying HLA class II alleles that have been linked to an autoimmune disease**.

           DQA1                DQB1                DRB1                                                     
  -------- ------------------- ------------------- ---------------- ------------------- ------------------- -------------------
  RECP02   DQA1\*05:01:01:01   DQA1\*02:01         DQB1\*02:01:01   DQB1\*02:02:01:01   DRB1\*03:01:01:01   DRB1\*07:01:01:01
  RECP32   DQA1\*05:01:01:01   DQA1\*04:01:01      DQB1\*02:01:01   DQB1\*04:02:01      DRB1\*03:01:01:01   DRB1\*03:02:01
  RECP33   DQA1\*05:01:01:01   DQA1\*05:05:01:01   DQB1\*02:01:01   DQB1\*03:19         DRB1\*03:01:01:01   DRB1\*11:02:01
  RECP37   DQA1\*05:01:01:01   DQA1\*01:03:01:01   DQB1\*02:01:01   DQB1\*06:03:01      DRB1\*03:01:01:01   DRB1\*13:01:01
  RECP26   DQA1\*01:02:01:01   DQA1\*05:05:01:01   DQB1\*06:02:01   DQB1\*03:01:01:01   DRB1\*15:01:01:01   DRB1\*01:03
  RECP39   DQA1\*01:02:01:01   DQA1\*03:02         DQB1\*06:02:01   DQB1\*03:03:02:01   DRB1\*15:01:01:01   DRB1\*09:01:02
  RECP42   DQA1\*01:02:01:01   DQA1\*02:01         DQB1\*06:02:01   DQB1\*02:02:01:01   DRB1\*15:01:01:01   DRB1\*07:01:01:01
  RECP49   DQA1\*01:02:01:01   DQA1\*01:02:01:01   DQB1\*06:02:01   DQB1\*06:09:01      DRB1\*15:01:01:01   DRB1\*13:02:01
  RECP50   DQA1\*01:02:01:01   DQA1\*02:01         DQB1\*06:02:01   DQB1\*02:02:01      DRB1\*15:01:01:01   DRB1\*07:01:01:01

*RECP, Rasmussen Encephalitis Children's Project*.

Higher TCR Clonality in Brain versus Matched Blood {#S3-2}
--------------------------------------------------

We compared the TCR β CDR3 amino acid sequences in brain and matched blood samples from 14 RE surgeries. To obtain an overall measure of the diversity of the CDR3 sequences in each sample, a clonality score was calculated. Clonality is defined as 1 minus the normalized Shannon's Diversity Index, and varies from 0, maximal diversity, to 1 in a completely oligoclonal sample. Evenness metrics such as clonality allow comparisons to be made between samples that vary in sequencing depth ([@B26]). As shown in Figure [1](#F1){ref-type="fig"} the diversity of CDR3 sequences in the brain was significantly less than in the blood, although the clonality of the brain specimens varied, and the clonal composition of one of the blood samples was clearly skewed. To further explore the differences between the brain and blood TCR repertoires, we analyzed the length distribution of nucleotide sequences that specified each CDR3 amino acid sequence. In Figure [2](#F2){ref-type="fig"}, these distributions are represented as a heat map following Euclidean clustering. All of the brain samples and all except one of the blood samples are clustered. The outlier, RECP47 corresponds to the blood sample with the high clonality score (Figure [1](#F1){ref-type="fig"}). The CDR3 length distributions in the blood were centered at 42 and 45 nucleotides whereas the CDR3 length distributions in the brain appeared to be more variable. Five of the brain samples peaked at shorter (RECP33, RECP40, and RECP49) or longer (RECP37 and RECP42) nucleotide sequence lengths; RECP45 contained an additional peak at 57 nucleotides. It has been documented that CDR3 length distributions from healthy individuals follow a Gaussian-like distribution ([@B34]). We fitted all of the CDR3 distributions to a normal curve and applied the Kolmogorov--Smirnov statistic to assess Goodness-of-Fit. The RECP49 brain sample was the only case that deviated significantly from a Gaussian distribution according to this analysis, although RECP42 approached significance (Figure S1 in Supplementary Material). However, in four cases (RECP33, RECP35, RECP42, and RECP49), the relative frequency of Vβ genes significantly differed between brain and blood (Figure S2 in Supplementary Material). This could be attributed to the overrepresentation of one particular Vβ gene in the RE brain samples, and may reflect the presence of one or more highly abundant T cell clone in the brain.

![**Clonal restriction of αβ T cells in resected brain tissue from surgeries to treat Rasmussen encephalitis compared with matched blood samples collected at the time of surgery**. The frequencies of unique CDR3 amino acid sequences in each brain and blood specimen were used to calculate a clonality score. Stacked dot/box plots with median clonality scores show that the repertoire of T cells in the brain is significantly less diverse than in the circulation (*N* = 14 patients). *P* value was determined by the Wilcoxon signed-rank test.](fimmu-07-00608-g001){#F1}

![**Length distribution of CDR3 sequences in Rasmussen encephalitis brain and blood samples**. The lengths in nucleotides of all of the CDR3 sequences in brain and matched blood specimens were compiled, and the frequency distributions were used to generate a heat map.](fimmu-07-00608-g002){#F2}

Overlap of CDR3 Sequences between Brain and Blood {#S3-3}
-------------------------------------------------

A pairwise comparison of the CDR3 amino acid sequences in each brain and matched blood sample revealed that there were both shared sequences and sequences that were only found in the brain (Figure [3](#F3){ref-type="fig"}). In the case of RECP48 there was no overlap likely due to the paucity of CDR3 sequences in the brain tissue specimen. Comparison of the nucleotide sequences encoding the shared CDR3 sequences indicated that some of the T cells in the brain and the blood that expressed the same CDR3 amino acid sequence originated from different clonal lineages (Figure S3 in Supplementary Material). We next determined if any of the CDR3 amino acid sequences in the brain samples were found in more than one brain sample, which proved to be the case (Figure [4](#F4){ref-type="fig"}A). Comparing the sequences in four brain samples that had the highest number of shared sequences seen in a pair-wise comparison identified three overlapping sequences (Figure [4](#F4){ref-type="fig"}B). As expected they were encoded by different nucleotide sequences. In the paper by Schneider-Hohendorf et al. the CDR3 sequence CASSLGTDTQYF shared by RECP40, RECP42 and RECP45 was also found in CD8^+^ PBMCs from five RE patients ([@B20]). RECP40, RECP42 and RECP45 all carry the HLA class I allele C\*07:01:01:01 (Table S1 in Supplementary Material). We looked for all of the sequences that were present in three or more brain samples and found 15 more CDR3 sequences. We compared them with the sequences in the RE blood samples, and in reference groups of blood from 12 focal cortical dysplasia (FCD) cases and two tuberous sclerosis complex (TSC) cases, and 100 healthy individuals. As shown in Table [4](#T4){ref-type="table"}, none of the 18 CDR3 sequences were unique to the RE brain samples, which means that there were public T cell clones in the RE brain samples. Strikingly 12 of these sequences were found in \>90% of the cohort of healthy individuals, indicating that they correspond to very common T cell clones. Two pairs of the CDR3 sequences differ by only one amino acid suggesting that each pair may recognize the same epitope (Table [4](#T4){ref-type="table"}).

![**CDR3 sequence overlap between matched brain and blood specimens**. All of the different CDR3 sequences in brain and matched blood specimens were counted. The results are displayed as Venn diagrams. Average overlap is 14.7% of the brain repertoire.](fimmu-07-00608-g003){#F3}

![**CDR3 sequence overlap between RE brain specimens**. **(A)** Pairwise comparison of CDR3 sequences from 14 RE brain specimens showing the number of sequences found in more than one brain specimen. **(B)** Cross comparison between cases with the highest number of shared sequences (RECP34, RECP40, RECP42, and RECP45). Venn diagrams show that there is no overlap at the nucleotide level. Nucleotide differences are shown in red.](fimmu-07-00608-g004){#F4}

###### 

**Incidence of overlapping CDR3 sequences**.

  CDR3 (amino acid)   RE brain (%)   RE blood (%)   FCD/TSC blood (%)   Normal blood (%)
  ------------------- -------------- -------------- ------------------- ------------------
  CASSLGTDTQYF        36             64             71                  99
  CASSLSTDTQYF        29             50             57                  100
  CASSLGETQYF         29             93             79                  100
  CASSLGGTEAFF        21             71             64                  100
  CASSSQETQYF         21             57             79                  100
  CASSLGYEQYF         21             79             79                  99
  CASSPGYEQYF         21             29             64                  92
  CASSLGQNTEAFF       21             86             64                  100
  CASSIQGNTEAFF       21             7              21                  69
  CASSPLGSSYNEQFF     21             0              7                   46
  CASSLGQGNTGELFF     21             36             36                  83
  CASSPRDSYEQYF       21             21             29                  68
  CASRLGGGTEAFF       21             0              14                  19
  CASSFYNEQFF         21             29             29                  92
  CASSPNTEAFF         21             50             57                  93
  CASSPSGSSYEQYF      21             29             7                   73
  CASSLAGGTDTQYF      21             57             71                  99
  CASSSAYEQYF         21             36             64                  96

*CDR3, third complementarity region; RE, Rasmussen encephalitis; FCD, focal cortical dysplasia; TSC, tuberous sclerosis complex*.

Abundant Private and Public T Cell Clones in RE Brain Tissue {#S3-4}
------------------------------------------------------------

The high clonality scores, and skewing of Vβ gene usage and CDR length distributions clearly indicated that there were a number of abundant T cell clones in the RE brain samples. In Table [5](#T5){ref-type="table"} the CDR3 sequences comprising the top \~5% of CDR3 sequences in each brain sample are tabulated; none of the sequences are shared. These sequences appear to account in large measure for the skewing of the distributions of Vβ gene usage and CDR3 length. Several of the sequences were also found in the matched blood sample albeit at a much lower frequency, but with one exception. The top sequence in RECP47 brain is also the top sequence in RECP47 blood, and its frequency in the blood exceeds that of the brain. This explains the outlier in the plot of clonality scores of the blood samples shown in Figure [1](#F1){ref-type="fig"}. Similarly the two brain samples with the highest clonality scores correspond to RECP42 and RECP49 in which 47and 70%, respectively, of the CDR3 sequences are identical. Nineteen of the CDR3 sequences in the brain samples are associated with more than one TRBV gene (Table [5](#T5){ref-type="table"}). However, except for one of the two CDR3 sequences in RECP40, one Vβ gene is associated with 97--99% of the CDR3 sequence (Table S2 in Supplementary Material). In the RECP40 brain the top two CDR3 sequences only differ by one amino acid suggesting that the same epitope may be recognized (Table [5](#T5){ref-type="table"}).

###### 

**Top CDR3 sequences in Rasmussen encephalitis brain specimens from the study cohort**.

  Case ID               CDR3 (amino acid)     CDR3 length (nt)   Brain (%)      TRBV gene              Blood (%)   TRBV gene
  --------------------- --------------------- ------------------ -------------- ---------------------- ----------- --------------
  RECP32                CASSQDEGDEQYF         39                 9.22           3                      0           n.a.
  CASSLNPDRGIYEQFF      48                    5.01               7              0                      n.a.        
  RECP33                CAISESNYGYTF          36                 22.26          6,10                   0.13        6,10
  CASSLLVVESELHTGELFF   57                    13.47              4,5            0.004                  5           
  CASSDSRGNIQYF         39                    6.08               6              0                      n.a.        
  CASSKTSGPDNEQFF       45                    5.40               7,11           0.004                  7           
  RECP34                CASAEEWSSYNSPLHF      48                 6.65           6,10                   0           n.a.
  CASTLLRDTDTQYF        42                    4.89               2              0.027                  2           
  CASSQDTPGQFYEQYF      48                    4.62               1,4,5,7,13     0                      n.a.        
  RECP35                CASSLRGTGNTEAFF       45                 8.07           2,4,7,12,19,27,28,30   0           n.a.
  CASGPGGPSTGELFF       45                    7.18               12,13          0.003                  13          
  CASSTSSTDTQYF         39                    5.15               2,6            0                      n.a.        
  RECP37                CASSQDPQGALNEQFF      48                 17.13          4,5,7,11               0.009       4
  CASSYRPESYNEQFF       45                    6.83               6              0.044                  6           
  CASGRGTSGPTGELFF      48                    4.95               12             0.003                  12          
  RECP40                CASSVAYEQYF           33                 12.31          2,3,6,10,12,25,27      0.006       6
  CASAVAYEQYF           33                    9.85               3,6,10,12,27   0                      n.a.        
  RECP42                CASSVDHRAGKPYEQYF     51                 47.03          5,19                   0.008       19
  CATSVTTGGYTEAFF       45                    9.61               12,24          0.059                  24          
  CASSGGSTDTQYF         39                    8.75               4,19           0.004                  19          
  RECP43                CASSTPGQGIGGYTF       45                 15.44          19                     0           n.a.
  CASSLQDRGPGGEQYV      48                    5.65               7,11           0                      n.a.        
  RECP45                CASSLRNYDDRVGYYEQYF   57                 13.38          6,12,27,28             0.003       27
  CASSLGTGDRSNQPQHF     51                    6.94               6,28           0.009                  28          
  RECP46                CASTLQMNTEAFF         39                 5.62           6                      0.005       6
  RECP47                CASGYEGGSTEAFF        42                 9.60           12                     15.09       7,12
  RECP48                CASSSDGNTGELFF        42                 7.49           5                      0           n.a.
  RECP49                CASQLGAATGYTF         39                 70.02          4,5,7,11               3.8         3,4,5,6,7,11
  RECP50                CASSPDRVETQYF         39                 12.15          7                      0           n.a.
  CVSSPGVPFTRFNTEAFF    54                    8.40               12             0                      n.a.        
  CASSLSSFQETQYF        42                    5.14               7,11           0                      n.a.        

*CDR3, third complementarity region; RECP, Rasmussen Encephalitis Children's Project; n.a., not applicable*.

We compared the 31 CDR3 sequences that comprised the top \~5% of sequences in the RE brain samples with our sequence data from the 28 RE and FCD/TSC blood samples as well as the cohort of 100 healthy blood donors. As shown in Table [6](#T6){ref-type="table"} 18 of the sequences were only found in the brain or in the matched blood sample; however, the remaining CDR3 sequences were not specific to RE. Based on the number of nucleotide insertions and deletions at the VβDβ and DβJβ boundaries, the distance of the private (patient-specific) TCRβ CDR3 sequences from germline was greater than that of the public TCRβ CDR3 sequences (Figure [5](#F5){ref-type="fig"}). It has been reported that the CDR3 sequences in CD8^+^ T cell clones that are shared between individuals contain fewer nucleotide insertions ([@B35]). Two of the public CDR3 sequences in two RE cases differed by a single amino acid from the CDR3 sequences found in two cytotoxic T cell clones that recognize an influenza A virus epitope ([@B36]) (Table [7](#T7){ref-type="table"}). Both of the clones directed against the influenza virus were HLA-A\*02:01-positive whereas neither RE case carried this allele (Table [7](#T7){ref-type="table"}). However, the two HLA-A alleles carried by the RE patients are associated with HLA supertypes that are known to bind influenza virus peptides ([@B37], [@B38]).

###### 

**Incidence of public CDR3 sequences**.

  CDR3 (amino acid)     RE blood (%)   FCD/TSC blood (%)   Normal blood (%)
  --------------------- -------------- ------------------- ------------------
  CASSGGSTDTQYF         43             14                  69
  CASSVAYEQYF           14             14                  43
  CASSPDRVETQYF         0              7                   38
  CASSTSSTDTQYF         0              14                  25
  CASSSDGNTGELFF        0              0                   21
  CASSLRGTGNTEAFF       7              0                   17
  CAISESNYGYTF          7              7                   16
  CASSLSSFQETQYF        0              0                   6
  CASTLQMNTEAFF         7              0                   5
  CASSQDEGDEQYF         0              7                   2
  CASAEEWSSYNSPLHF      0              7                   2
  CASSTPGQGIGGYTF       0              0                   2
  CASAVAYEQYF           0              0                   1
  CASSLLVVESELHTGELFF   7              0                   0
  CASSKTSGPDNEQFF       7              0                   0
  CASTLLRDTDTQYF        7              0                   0
  CASGPGGPSTGELFF       7              0                   0
  CASSQDPQGALNEQFF      7              0                   0
  CASSYRPESYNEQFF       7              0                   0
  CASGRGTSGPTGELFF      7              0                   0
  CASSVDHRAGKPYEQYF     7              0                   0
  CATSVTTGGYTEAFF       7              0                   0
  CASSLRNYDDRVGYYEQYF   7              0                   0
  CASSLGTGDRSNQPQHF     7              0                   0
  CASGYEGGSTEAFF        7              0                   0
  CASQLGAATGYTF         7              0                   0
  CVSSPGVPFTRFNTEAFF    0              0                   0
  CASSLNPDRGIYEQFF      0              0                   0
  CASSDSRGNIQYF         0              0                   0
  CASSQDTPGQFYEQYF      0              0                   0
  CASSLQDRGPGGEQYV      0              0                   0

*CDR3, third complementarity region; RE, Rasmussen encephalitis; FCD, focal cortical dysplasia; TSC, tuberous sclerosis complex*.

![**Distance from germline of the most prevalent private and public clones in RE brain tissue**. The top five percent of CDR3 amino acid sequences in the RE brain samples comprise 133 public and 88 private TCR clones (based on Vβ Dβ, and Jβ usage and the number of nucleotide insertions and deletions at the Vβ/Dβ and Dβ/Jβ boundaries). Summing the number of nucleotide insertions and deletions at the Vβ/Dβ and Dβ/Jβ boundaries provides a measure of the distance from germline of the clone; a larger number reflects a greater distance. The difference between the private and public clones was statistically significant (*P* = \< 0.0001, Mann--Whitney test).](fimmu-07-00608-g005){#F5}

###### 

**CDR3 sequences in Rasmussen encephalitis brain that closely match influenza A virus-specific CDR3 sequences**.

  ID       CDR3             Human leukocyte antigen-A allele
  -------- ---------------- ----------------------------------
  RECP35   `CASSTSTDTQYF`   A\*29:02:01:01
  Z35705   `CASSTSTDTQYF`   A\*02:01
  RECP42   `CASSGSTDTQYF`   A\*11:01:01:01
  Z35681   `CASSGSTDTQYF`   A\*02:01

*IDs: RECP, Rasmussen Encephalitis Children's, Genbank accession number*.

*CDR3, third complementarity region*.

Discussion {#S4}
==========

We and others have reported that the majority of αβ T cells in affected brain parenchyma from RE surgeries are CD8^+^ ([@B9], [@B10], [@B13]), thus finding a number of shared HLA class I alleles among the 24 RE cases surveyed supports the involvement of antigen specific MHC class I-restricted T cells in RE. Two of the shared HLA class I alleles, HLA-C\*03:01:01:01 and HLA-C\*07:01:01:01 may predispose an individual to an autoimmune response. It has been reported that HLA-A\*03:01 confers susceptibility to MS independent of HLA class II risk alleles ([@B39]); the HLA-C\*03:01:01:01 allele is carried by a third of the RE cases in our study cohort. HLA-C\*07 has been linked to Graves disease, an autoimmune disorder that causes hyperthyroidism ([@B31]); 10 of the RE cases carry HLA-C\*07:01:01:01, and six patients carry both HLA-C\*03:01:01:01 and HLA-C\*07:01:01:01. Sixteen of the RE cases reported by Schneider-Hohendorf et al. were also typed as positive for the C\*07 allele ([@B20]). HLA-C\*07 is a ligand for activating and inhibiting killer immunoglobulin-like receptors (KIR) expressed by natural killer cells, and αβ and γδ T cells ([@B40]), and it has been suggested that a defect in KIR binding to HLA-C\*07 may account for the association of this HLA allele with autoimmunity ([@B31]).

We also found that several RE patients shared HLA class II alleles suggesting a role for CD4^+^ T cells in disease. Six of the RE patients in our study cohort carried DQA1\*04:01:01 and DQB1\*04:02:01 alleles. Both alleles were less frequent in a reference population from a similar demographic suggesting that they may be associated with an increased risk of RE. HLA typing a much larger number of RE patients will be necessary to determine whether these alleles are associated with the disease. Several patients in the study cohort carried HLA class II alleles that have been linked to type 1 diabetes and MS.

Although far fewer CD4^+^ T cells than CD8^+^ T cells are found in affected brain parenchyma, CD4^+^ T cells are nevertheless present in perivascular spaces and leptomeninges ([@B41], [@B42]). CD4^+^ T cells play a multiplicity of roles in cellular immunity and T cell dependent antibody responses, and both CD4^+^ effector T cells and follicular CD4^+^ helper T cells have been implicated in autoimmune diseases ([@B43], [@B44]). Circulating autoantibodies against neuronal proteins have been detected in blood from some RE patients ([@B45]--[@B48]), and clonal expansion of immunoglobulin heavy chains in RE brain tissue has been reported ([@B49]). In one case report treatment of a RE patient with rituximab reduced seizures ([@B5]).

We have obtained an unbiased sample of the αβ T cell repertoire in 14 RE surgery cases by targeted sequencing genomic DNA from resected brain tissue and blood. We cannot rule out the possibility that immunosuppressive treatments prior to surgery may have impacted the T cell repertoires that we obtained. Calculating clonality scores revealed that the clonal composition of T cells in the brain was less diverse than in blood collected from the same patients at the time of the surgery. On average only about 15% of the brain αβ T cell repertoire was found in the blood. Some of T cells in the brain and the blood that expressed the same CDR3 amino acid sequence originated from different clonal lineages. We recently showed that the majority of T cells in resected brain tissue from seven RE surgeries expressed the resident memory T cell marker CD103 ([@B50]), thus many of T cell clones in the brain might not be expected to be part of the pool of circulating central memory and effector memory T cells ([@B50]). Resident T~RM~ cells develop at a site of infection during the effector stage of an immune response, and persist long after clearance of the pathogen ([@B15]). We have suggested that local reactivation of T~RM~ cells may explain why inflammation usually remains confined to one cerebral hemisphere in RE ([@B50]). In support of this idea, reactivation of T~RM~ cells appears to account for the reoccurrence of psoriatic lesions at the same sites on the skin ([@B51]).

In the brain only 18 TCRβ CDR3 sequences were found that were shared by three or more RE patients. All of these rare sequences were also detected in blood samples from FCD and TSC surgeries, and in almost half of the blood samples collected from a cohort of healthy individuals. The pathological significance of the low frequency T cell clones that express these public TCRβ CDR3 sequences is not clear. On the other hand 13 of the 31 most abundant TCRβ CDR3 sequences (defined as the top 5% of sequences in the 14 brain specimens) were also found in blood from normal donors. Nine of these public CDR3 sequences were the most frequently detected sequence in nine of the brain specimens. The public CDR3 nucleotide sequences were less divergent from germline than the abundant private CDR3 nucleotide sequences, which may reflect their specificity for common pathogens ([@B35]). In support of this idea, two of the abundant public TCRβ CDR3 sequences differ by a single amino acid from CDR3 sequences that are known to recognize an influenza virus epitope (Table [7](#T7){ref-type="table"}) ([@B36]).

Structural or sequence similarity between pathogen peptides and self-peptides has been proposed as a cause of autoimmunity ([@B52]--[@B54]). In the Japanese population increased risk of RE has been linked to HLA-A\*02:01, 24:02, 26:01, and HLA-B\*46:01 ([@B55]). In the cohort of 24 RE cases that we analyzed, 41.7% of the patients carried HLA-A\*02:01:01:01, and 20.8% of the patients carried HLA-A\*24:02:01:01 (Table [1](#T1){ref-type="table"}). Both HLA-A\*02:01 and HLA-A\*24:02 are known to bind peptides from influenza virus ([@B38], [@B56]). Takahashi et al have suggested that cytotoxic CD8^+^ T cells in RE brain may have arisen due to molecular mimicry ([@B55]). It may not be necessary to invoke molecular mimicry to explain the development of autoreactive T cells in as much as an infection can lead to the generation of T cells that express two TCRs, one directed against a foreign antigen, and a second TCR that recognizes a self-antigen ([@B57]). Alternatively, an inflammatory milieu created by an infection can cause the activation of weakly self-reactive bystander T cells that have escaped tolerance mechanisms ([@B58]), which may explain the presence of abundant private clones in RE brain. The two most abundant TCRβ CDR3 sequences identified in this study were patient specific and may also be disease-specific. Given the prevalence of these two TCRβ CDR3 sequences in the brain tissue sampled, it may be possible to identify the corresponding Vα and TCRα CDR3 by sequencing the same genomic DNA. This would allow us to reconstruct functional TCRs for antigen discovery and disease modeling ([@B59], [@B60]).

Thirteen of the abundant private TCRβ CDR3 sequences were present at a low frequency in the matched blood samples except in the case of RECP47. The αβ T cell repertoire in RECP47 blood was dominated by the same abundant CDR3 sequence found in the brain indicating that clones expressing this sequence had expanded in the periphery. Clonal expansion of circulating CD8^+^ T clones has been previously reported in several RE patients ([@B20]).

The co-occurrence of four different autoimmune diseases, Hashimoto thyroiditis, ulcerative colitis, Crohn disease, and systemic lupus erythematosus in four different RE patients has led to the suggestion that genes that predispose to autoimmunity are risk factors for RE ([@B61]). Our finding that some RE patients in our study cohort carry HLA alleles that are known to confer susceptibility to different autoimmune diseases strongly supports this idea.
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